Search the Newsreel

United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns

Amgen exits TScan TCR discovery collaboration tied to over USD 500m in milestones

Amgen has terminated its research collaboration and license agreement with TScan Therapeutics, effectively removing over $500 million in potential milestone payments for TScan. The agreement, originally signed in May 2023, focused on using TScan's platform to identify antigens for Crohn's disease, with Amgen holding …

Astera Labs: Scorpio Is Becoming The Real Story (NASDAQ:ALAB)

Serabi Gold rallies as bullion nears records — are small producers finally being noticed?

Federal (FSS) Quarterly Figures: EPS Beats Its Estimate for the Current Session; Post-Earnings: Shares Close 0.53% Higher at the Close - Revenue Guidance Update

Why Briacell Therapeutics Corp stock surged yesterday

National (FIZZ) Earnings Snapshot: The Available Earnings Metric Delivers a Miss for This Review; Price Move: Shares Move 1.97% Up on the Day - Post-Earnings Reaction

From Legal & General (LSE:LGEN) To Kingfisher (LSE:KGF): What Is Separating Value Stocks Today?

Serabi Gold rebounds today — is record bullion pricing rewriting small-cap miner economics?

Kodal Minerals steadies today: can battery metals regain the spotlight from gold?

Why Legal And General Group (LSE:LGEN) And Prudential (LSE:PRU) Are Splitting The UK Financials Story

Kodal Minerals (LSE:KOD) Puts Penny Stocks Under An Earnings-Quality Spotlight

Generation Capital Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Premier African Minerals swings today — how volatile has junior lithium become?

Why Fortune Minerals Limited stock surged yesterday

How Investors May Respond To Peloton (PTON) Turning Profitable While Guiding For Lower 2027 Revenue

Rein Therapeutics receives FDA fast track for IPF drug LTI-03

Rein Therapeutics has been granted Fast Track designation by the FDA for its idiopathic pulmonary fibrosis (IPF) drug, LTI-03. This designation aims to accelerate the development and review process for LTI-03, an inhaled peptide therapy designed to inhibit lung scarring. The company is currently …

Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics has been granted FDA Fast Track designation for LTI-03, its drug for idiopathic pulmonary fibrosis (IPF), which will expedite its development and review. LTI-03 is a novel inhaled peptide therapy designed to slow lung scarring and promote healing, currently in a Phase …

Generac (GNRC) Stock Could Be Reasonable On Cash Flow Yet Stretched On Earnings

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Generac Holdings has delivered an 84.8% gain over the past three years, yet the valuation picture is mixed, with the intrinsic value estimate from …

WHK SEC Filings - WhiteHawk Minerals Corp. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for WhiteHawk Minerals Corp. (WHK) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading disclosures. Each filing is accompanied by expert analysis from Rhea-AI, offering insights into potential market impact, sentiment scores, and end-of-day stock performance data. …

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $29 from $28, maintaining a "buy" rating and projecting a 39.8% upside. Despite a recent quarterly loss of $0.41 per share and revenue below estimates, analyst sentiment remains largely positive, with a …

H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated a Buy rating for Seaport Therapeutics (NASDAQ:SPTX) with a $50.00 price target. The firm highlighted that the positive clinical data from a competitor's candidate could reduce competitive pressure for Seaport's GlyphAllo, and their non-hallucinogenic psychedelic candidate, Glyph2BLSD, could offer a …

Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Seaport Therapeutics (SPTX), setting a $50 price target, which suggests a 104.75% upside. Despite this, analyst sentiment remains mixed, leading to a consensus "Hold" rating with an average target of $38.40. The company recently reported a …

Federal Signal: Solid Fundamentals Keep The Buy Case Intact (NYSE:FSS)

FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival

Rein Therapeutics (NASDAQ: RNTX) announced that its lead candidate, LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis (IPF), has received Fast Track designation from the U.S. FDA. This designation aims to expedite development and review for serious conditions with unmet medical needs. The company …

Jerash Holdings to Present at Lake Street's 10th Annual Best Ideas Growth Conference, September 10

FAIRFIELD, NJ / ACCESS Newswire / August 20, 2026 / Jerash Holdings (US), Inc. (Nasdaq:JRSH), which manufactures and exports custom, ready-made, sportswear and outerwear in Jordan for leading global brands, today announced that Gilbert Lee, its chief financial officer, will participate at Lake Street …

General Dynamics stock holds steady as new Canadian weapons contract underpins Q2 2026 earnings beat

Motor & General Finance Ltd. Revenue Breakdown – NSE:MOTOGENFIN

Generac plans $250M factory expansion as AI fuels energy demand

[Industrial Generac generator on pad] J. Michael Jones/iStock Editorial via Getty Images Generac Holdings (GNRC [https://seekingalpha.com/symbol/GNRC]), a company best known for backup generators used during household power outages, is finding a major new source of growth in the artificial-intelligence boom. The Wisconsin-based manufacturer plans …

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright

HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company …

Radiopharm advances RAD202 trial to higher dose level By Investing.com

Radiopharm Theranostics has received approval from its Data Safety and Monitoring Committee to increase the dose level of its RAD202 radiotherapeutic to 180mCi in a Phase 1 clinical trial. The trial, named HEAT, is evaluating 177Lu-RAD202 in patients with HER2-positive advanced solid tumors. This …

TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD

This article provides a revenue breakdown for TherapeuticsMD, Inc. (NASDAQ: TXMD), highlighting that the greatest contribution to its revenue came from the United States, accounting for $1.79 million USD last year and $1.12 million USD the year prior. The data is presented through TradingView, …

Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest Trading - Profit Growth Outlook

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response

Q4 EPS Estimates for General Motors Lifted by Zacks Research

Zacks Research has increased its Q4 2026 EPS estimate for General Motors (GM) to $2.56, up from $2.52, while analysts maintain a "Moderate Buy" rating with a $101.41 average price target. GM recently surpassed quarterly expectations with $3.57 EPS and $48.03 billion in revenue, …

UBS raises Iovance Biotherapeutics stock price target on revenue beat